false 0001488039 0001488039 2021-09-07 2021-09-07
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): September 8, 2021 (September 7, 2021)
 
Atossa Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
         
Delaware
 
001-35610
 
26-4753208
(State or other jurisdiction of
incorporation)
 
(Commission File Number)
 
(I.R.S. Employer
Identification No.)
 
107 Spring Street
Seattle, Washington
 
98104
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (206) 325-6086
 
Not Applicable
Former name or former address, if changed since last report
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuance to Section 12(b) of the Act:
 
Title of each class
Trading symbol(s)
Name of each exchange on which registered
Common Stock, $0.18 par value
ATOS
Nasdaq
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
 
Emerging growth company    ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐
 
 
 

 
 
Item 5.07 Submission of Matters to a Vote of Security Holders
 
On September 7, 2021, Atossa Therapeutics, Inc. (the “Company”) convened a Special Meeting of Stockholders (the “Meeting”) for the purpose of approving an amendment to the Company’s charter to increase authorized shares of common stock by 100 million shares (the “Proposal”).
 
As of the Meeting date, approximately 73% of the votes cast have been voted in favor of the Proposal. However, the Proposal requires the vote of a majority of the shares of common stock issued and outstanding as of the record date and the votes cast in favor represent approximately 42% of shares outstanding on the record date. Atossa is therefore adjourning the meeting for 30 days, until October 7, 2021, 9 am Eastern time, to allow additional time for voting on this Proposal.
 
 
* * *
 
 
 

 
 
SIGNATURES
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
Date: September 8, 2021
Atossa Therapeutics, Inc. 
 
     
 
By:  
/s/ Kyle Guse 
 
   
Kyle Guse
 
   
Chief Financial Officer, General Counsel and Secretary 
 
 
 
 
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Atossa Therapeutics Charts.
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Atossa Therapeutics Charts.